# A Clinical Study to Assess the Efficacy of Adjuvant Immunotherapy With Cemiplimab in Patients With Surgically Removed Non-small Cell Lung Cancer Who Have Not Re

Source: https://onco.cc/trials/nct06931717/  
OnCo record `nct06931717` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of cemiplimab in lung cancer, run by ETOP IBCSG Partners Foundation, now recruiting.

## Summary

A Clinical Study to Assess the Efficacy of Adjuvant Immunotherapy With Cemiplimab in Patients With Surgically Removed Non-small Cell Lung Cancer Who Have Not Received Prior Chemotherapy is a phase 3, randomised interventional study registered as NCT06931717 by ETOP IBCSG Partners Foundation, with a registry enrolment figure of 390 participants, started 2026-01-12 and due to reach its primary completion in 2029-03. Interventions recorded: Cemiplimab. Conditions listed: Non-Small Cell Lung Cancer. Primary outcome: Disease-free survival (DFS). Lung eligibility wording from the registry: "* Pathological stage II-IIIA (UICC/ AJCC staging 9th edition) NSCLC Brain imaging should have been performed to complete staging, either preoperatively or postoperatively". Sites: Austria, Estonia, France, Germany, Ireland, Italy, Singapore, Spain, Switzerland. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-25
- Also known as: ARCH
- Tags: ctgov-ingest; lung-deep-dive
- Registry id: NCT06931717
- Phase: 3
- Setting: A Randomised Phase III Trial of Adjuvant Cemiplimab in Patients With Resected Stage II-IIIA NSCLC Who Have Not Received Prior Adjuvant Chemotherapy
- Sponsor: ETOP IBCSG Partners Foundation
- Enrolled: 390

## Sources

- ClinicalTrials.gov NCT06931717: https://clinicaltrials.gov/study/NCT06931717

## Connected records

- cancers: [Resectable stage I to III non-small-cell lung cancer](https://onco.cc/cancers/resectable-nsclc/)
- technologies: [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/)
- drugs: [Cemiplimab](https://onco.cc/drugs/cemiplimab/)
- companies: [Regeneron](https://onco.cc/companies/regeneron/)
- terms: [Lung cancer trials open today (registry snapshot)](https://onco.cc/terms/lung-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct06931717.json